stoxline Quote Chart Rank Option Currency Glossary
  
Eyenovia, Inc. (EYEN)
1.82  0.05 (2.82%)    02-19 16:00
Open: 1.75
High: 1.86
Volume: 106,272
  
Pre. Close: 1.77
Low: 1.7
Market Cap: 4(M)
Technical analysis
2025-02-19 4:40:08 PM
Short term     
Mid term     
Targets 6-month :  5.72 1-year :  8.03
Resists First :  4.9 Second :  6.88
Pivot price 2.13
Supports First :  1.7 Second :  1.41
MAs MA(5) :  1.85 MA(20) :  2.65
MA(100) :  18.11 MA(250) :  51.27
MACD MACD :  -1.4 Signal :  -1.7
%K %D K(14,3) :  5.9 D(3) :  5.4
RSI RSI(14): 28.5
52-week High :  205.6 Low :  1.7
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ EYEN ] has closed above bottom band by 30.7%. Bollinger Bands are 87.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.86 - 1.87 1.87 - 1.88
Low: 1.68 - 1.69 1.69 - 1.7
Close: 1.8 - 1.82 1.82 - 1.83
Company Description

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

Headline News

Wed, 05 Feb 2025
Revolutionary Eye Drop Spray Shows Perfect Precision: Eyenovia's Game-Changing Solution for Millions - StockTitan

Wed, 05 Feb 2025
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device - GlobeNewswire

Tue, 28 Jan 2025
Major Shake-up at Eyenovia: Massive 80:1 Share Consolidation Coming February - StockTitan

Tue, 28 Jan 2025
Eyenovia Announces 1-for-80 Reverse Stock Split - GlobeNewswire

Wed, 15 Jan 2025
Eyenovia Announces Leading Proxy Advisory Firms, ISS and - GlobeNewswire

Fri, 06 Dec 2024
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 2 (M)
Held by Insiders 992240 (%)
Held by Institutions 0.8 (%)
Shares Short 57 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.565e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -451 %
Return on Assets (ttm) 195.5 %
Return on Equity (ttm) -79.7 %
Qtrly Rev. Growth 31830 %
Gross Profit (p.s.) 28.47
Sales Per Share -310.43
EBITDA (p.s.) -4.52e+006
Qtrly Earnings Growth -55.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -30 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.66
Stock Dividends
Dividend 0
Forward Dividend 55850
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android